High-Dose, Extended Half-Life IL-23 Inhibitors: the Next Big Step in Psoriasis Care?
{{output}}
Biologic therapies targeting the interleukin (IL)-23 and IL-17 pathways represent the current standard of care for moderate-to-severe psoriasis, with demonstrated high efficacy and favorable safety profiles. However, many patients still experience residual dis... ...
